By Fineline Cube 
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has approved its 5mg tablet formulation of Evrysdi (risdiplam) for spinal muscular atrophy (SMA) patients. The decision is based on results from a bioequivalence study (NCT04718181) that confirmed the 5mg tablet formulation of Evrysdi is bioequivalent to the oral solution.
Therapeutic Advantages
Evrysdi represents the first and only non-invasive, at-home disease-modifying therapy for SMA. The 5mg tablet formulation is suitable for patients aged ≥2 years and weighing ≥20kg (44lbs) who can swallow without feeding tubes. The tablets can be taken whole or dissolved in water, offering flexibility in administration.
Patient Convenience
The 5mg tablet can be taken with or without food and can be stored at room temperature, making it convenient for patients to manage their treatment at home.-Fineline Info & Tech